November 9–15, 2026 | Issue #24
Hey friend, welcome back to Last Week in Cannabis. This week we look at Quebec’s latest retail results, how Canadian producers are leaning on exports, and updates from the Netherlands and Australia. We also cover a new study on how men and women respond to THC. Let’s get into it.
1. CANADA: Quebec’s Government-Run Cannabis Retailer Reports 10% Sales Growth
Quebec’s provincial cannabis retailer reported sales of $207.5 million for the second quarter of its 2026–27 fiscal year, up about 10% from $189.4 million in the same quarter a year earlier. Volume rose 8%, from 38,957 kilograms to 42,028 kilograms, and transactions increased from 4.8 million to 5.2 million. The average price per gram, including taxes, edged up from $5.55 to $5.61. The retailer credits six new stores opened since last year, the launch of vape products in November 2025, and adjusted opening hours. It also says the growth reflects purchases moving from the illegal market to the legal market.
Mary Jane’s Take: When volume and transactions grow while the price per gram stays nearly flat, it suggests that more people are shopping rather than that prices are climbing. The claim that sales are shifting from the illegal market is the retailer’s own interpretation, and independent surveys are the better way to measure that over time. Still, steady growth in a mature market is a useful sign of how well legal access is working.
2. CANADA: Canadian Producers Lean on Exports as Pricing Allegations Resurface Abroad
Several Canadian licensed producers reported quarterly results over the past two weeks, and international sales were a common theme. One producer reported 22% net revenue growth, led by a 141% rise in international cannabis sales. Another reported $86 million in net revenue, with an export surge led by demand from Germany and Poland. A third reported record net revenue of $49.5 million for the three months ended September 30.
At the same time, allegations that Canadian producers sell cannabis below cost in overseas markets have resurfaced. Israel remains the only country to take formal action over those claims, and its trade investigation now names four Canadian producers. Producers have denied the allegations.
Mary Jane’s Take: Canada’s domestic market is mature, so it makes sense that producers look abroad for growth, particularly to medical markets in Europe. The trade-off is exposure to foreign regulators and trade disputes. For consumers here at home, the practical effect is that Canadian producers are building products and quality standards aimed at some of the strictest markets in the world. Whether the allegations lead to further action elsewhere is worth watching.
3. NETHERLANDS: A December Tender Is Planned for Medical Cannabis Supply After the Country’s Only Government-Approved Grower Goes Bankrupt
A Dutch court declared the Netherlands’ only government-approved medical cannabis grower bankrupt on October 8, 2026. In a November 6 letter to parliament, the health minister said the government’s medical cannabis office will publish a European tender in December 2026, select a supplier in May 2027 and begin deliveries in September 2027. Current forecasts show stored supplies of the individual varieties running out between early in the second quarter and the middle of the third quarter of 2027. The ministry acknowledged that patients will need to switch products during 2027.
The bankruptcy trustees have selected a restart bid for the grower’s Dutch operations, pending a supervisory judge’s approval. A planned law change to end the government’s trading monopoly has been delayed, with a target date of July 1, 2028. Parliament is scheduled to debate the situation on November 26.
Mary Jane’s Take: Medical cannabis patients depend on steady, consistent supply, so a gap between stockpiles and new supply is a serious concern. If you or someone you know uses medical cannabis in the Netherlands, the best step is to speak with a pharmacist or prescriber early about what options exist. This is also a reminder of how closely supply, regulation and patient care are linked.
4. AUSTRALIA: A Committee Declines to Change Drug-Driving Rules for Medical Cannabis Patients in the Australian Capital Territory
A committee of the Australian Capital Territory’s Legislative Assembly has advised against a bill that would give prescribed medical cannabis patients a legal defence to drug-driving charges when they are not impaired. The committee concluded there is not a “sufficient basis” for removing the existing presence-based offence for THC. It cited the current state of medical understanding, police capability and the difficulty of verifying lawful use. About 10,600 ACT patients were prescribed medicinal cannabis between June 2024 and June 2026. The bill’s sponsor argued that people prescribed other medicines, such as opioids and benzodiazepines, are judged on impairment rather than on the presence of a drug.
Mary Jane’s Take: There are two separate questions here. Driving while impaired is illegal everywhere, and nobody is arguing otherwise. The debate is whether a law should be based on impairment or on the mere presence of THC, which can remain detectable long after any effect has passed. Policies differ from place to place, so if you use medical cannabis and drive, it is important to know the rules where you live.
5. UNITED STATES: A Small UCLA Study Finds Occasional Male Cannabis Users Reported Stronger Effects Than Women
A study published online on October 29, 2026 in the journal Neuropsychopharmacology examined 44 healthy adults aged 21 to 55, split evenly between men and women. Researchers at the University of California, Los Angeles compared people who used cannabis occasionally with those who used it frequently. Among occasional users, men reported feeling more high, sedated and impaired than women, even though both groups had similar peak THC levels in their blood. Among frequent users, men and women responded similarly, and frequent users were more likely to say they liked the effects and chose to take more during the study.
The researchers note several limits. The sample was small, several findings came from exploratory analyses that need confirmation in larger studies, and the THC strengths tested were lower than those in many products sold today.
Mary Jane’s Take: This study is a reminder that people respond to cannabis differently, and that experience level matters as much as anything else. It does not mean that all men or all women will react in a particular way. The safest approach stays the same for everyone: start with a low dose, wait to see how it affects you, and increase slowly if you choose to.
That’s your week, with two stories from Canada and three from around the world. See you next Monday.
Mary Jane